HIGHLIGHTS
- who: Ilari Mu00e4ki-Opas from the Health Technology, Tampere University and Tampere University Hospital, Tampere, Finland have published the research: TRPA1 as a potential factor and drug target in scleroderma: dermal fibrosis and alternative macrophage activation are attenuated in TRPA1-deficient mice in bleomycin-induced experimental model of scleroderma, in the Journal: (JOURNAL)
- what: The authors investigated the role of TRPA1 in bleomyu2011 cin-induced skin fibrosis mimicking scleroderma. The model has features of an IL-4 mediated fibrosis which mainly results as collagen accumulation, but TGF-u03b2 mediated fibrosis could also be studied in . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.